TEAM Stock Recent News
TEAM LATEST HEADLINES
Enterprise software maker Atlassian beat second-quarter revenue estimates on Thursday, driven by a surge in demand for its artificial intelligence products.
Although the revenue and EPS for Atlassian (TEAM) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Atlassian (TEAM) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.45 per share a year ago.
Atlassian (NASDAQ: TEAM) stock price continued its remarkable rally ahead of its quarterly results. The shares surged to $260 on Tuesday, meaning it has jumped by more than 120% from its lowest point in November 2022.
Atlassian: GAAP Profitability, Accelerating Top-Line Growth Ahead (Ratings Upgrade)
Atlassian's (TEAM) Q2 performance is likely to have benefited from the rising adoption of cloud-based solutions, along with the enhancement of its portfolio through AI implementation and buyouts.
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Atlassian (TEAM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
Team Anywhere/SAN FRANCISCO--(BUSINESS WIRE)--Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced that it will release financial results for its second quarter of fiscal year 2024 ended December 31, 2023 after market close on Thursday, February 1, 2024. Atlassian will host a webcast and conference call to discuss the financial results at 2:00 P.M. Pacific Time. In conjunction with its earnings press release, Atlassian will po.
Atlassian (TEAM) appears to be an attractive investment option at the moment, with its strong portfolio, healthy demand environment and robust financials.
ASML dominates an incredibly valuable niche in the semiconductor supply chain. Pharmaceutical giant Roche sports an impressive product pipeline and attractive valuation.